Vertex expands pipeline as R&D spending surges to $5.1bn in 2024
Overview Vertex Pharmaceuticals reported a 12% increase in full-year product revenue, driven by strong demand for TRIKAFTA®/KAFTRIO® and the successful global launch of new therapies. In Q4, revenue grew to $2.91bn, with U.S. net product revenue up 17% and international revenue rising 14%. The company also made significant regulatory progress, with the U.S. approval of…
